Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

Berkshire Hathaway Class B shares (BRK.B) trade at $493.54, down 0.41% on the day, with a mixed technical picture showing bearish signals but bullish moving averages. Analyst consensus is positive with 57% buy ratings, though key financial ratios are not provided in the available data. The stock lacks recent news catalysts but maintains strong institutional interest.

Outlook remains cautiously optimistic given analyst support, but risks include market volatility and the company's exposure to broad economic cycles. Investment opportunity hinges on Berkshire's diversified holdings and management strength, balanced by the absence of current fundamental metrics for deeper valuation assessment.